<DOC>
	<DOC>NCT02933762</DOC>
	<brief_summary>The primary purpose of this study is to investigate the effects of JNJ-54175446 (dose response) on levels of Aβ fragments (Aβ1-42, Aβ1-40, Aβ1-38, Aβ1-37) in plasma and cerebrospinal fluid (CSF), the effects of JNJ-54175446 on markers of (neuro) inflammation/protection in blood and CSF and the pharmacokinetics of JNJ-54175446 followed by single and multiple dose administration.</brief_summary>
	<brief_title>A Study in Healthy Participants to Evaluate the Effect of JNJ-54175446 on Amyloid Biomarkers and Cytokine Profiles in Cerebrospinal Fluid and Plasma</brief_title>
	<detailed_description />
	<criteria>Participants must have a body mass index (BMI) between 18 and 32 kilogram (kg)/ meter (m)^2, inclusive (BMI = weight/height^2) Participant must be healthy on the basis of physical examination, medical history, vital signs, and 12lead electrocardiogram (ECG) Part 1 and 2 (Elderly Participants): Healthy male or female participants between 55 and 75 years of age, inclusive Participant must be healthy on the basis of both physical and neurological examination performed at Screening and at admission to the clinical unit Part 1 (Young Participants): Healthy male participants between 18 and 45 years of age, inclusive Participant has a history of or current liver or renal insufficiency; significant cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances, any inflammatory illness or any other illness that the Investigator considers should exclude the participant Participant has a history of hepatitis B surface antigen (HBsAg) or hepatitis C antibody (antiHCV) positive, or other clinically active liver disease, or tests positive for HBsAg or antiHCV at Screening (per Screening evaluations) Participant has a history of human immunodeficiency virus (HIV) antibody positive, or tests positive for HIV at Screening (per Screening evaluations) Participant has a history of malignancy within 5 years before Screening Participant has signs of increased intracranial pressure based on fundoscopy at Screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>